Diagnosing Zika virus infection against a background of other flaviviruses: Studies in high resolution serological analysis.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Sanabani, Sabri S
Sall, Amadou A
Abd El Wahed, Ahmed
MetadataShow full item record
AbstractBACKGROUND: Antibody-mediated targeting of regulatory T cell receptors such as CTLA-4 enhances antitumor immune responses against several cancer entities including malignant melanoma. Yet, therapeutic success in patients remains variable underscoring the need for novel combinatorial approaches. METHODS: Here we established a vaccination strategy that combines engagement of the nucleic acid-sensing pattern recognition receptor RIG-I, antigen and CTLA-4 blockade. We used in vitro transcribed 5'-triphosphorylated RNA (3pRNA) to therapeutically target the RIG-I pathway. We performed in vitro functional analysis in bone-marrow derived dendritic cells and investigated RIG-I-enhanced vaccines in different murine melanoma models. FINDINGS: We found that protein vaccination together with RIG-I ligation via 3pRNA strongly synergizes with CTLA-4 blockade to induce expansion and activation of antigen-specific CD8+ T cells that translates into potent antitumor immunity. RIG-I-induced cross-priming of cytotoxic T cells as well as antitumor immunity were dependent on the host adapter protein MAVS and type I interferon (IFN-I) signaling and were mediated by dendritic cells. INTERPRETATION: Overall, our data demonstrate the potency of a novel combinatorial vaccination strategy combining RIG-I-driven immunization with CTLA-4 blockade to prevent and treat experimental melanoma. FUND: German Research Foundation (SFB 1335, SFB 1371), EMBO, Else Kröner-Fresenius-Foundation, German Cancer Aid, European Hematology Association, DKMS Foundation for Giving Life, Dres. Carl Maximilian and Carl Manfred Bayer-Foundation.
CitationSci Rep. 2019 Mar 6;9(1):3648. doi: 10.1038/s41598-019-40224-2.
AffiliationHZI, Helmholtz Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig Germany.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Diagnosis of Zika Virus Infection by Peptide Array and Enzyme-Linked Immunosorbent Assay.
- Authors: Mishra N, Caciula A, Price A, Thakkar R, Ng J, Chauhan LV, Jain K, Che X, Espinosa DA, Montoya Cruz M, Balmaseda A, Sullivan EH, Patel JJ, Jarman RG, Rakeman JL, Egan CT, Reusken CBEM, Koopmans MPG, Harris E, Tokarz R, Briese T, Lipkin WI
- Issue date: 2018 Mar 6
- Identification of diagnostic peptide regions that distinguish Zika virus from related mosquito-borne Flaviviruses.
- Authors: Lee AJ, Bhattacharya R, Scheuermann RH, Pickett BE
- Issue date: 2017
- Antibody-based assay discriminates Zika virus infection from other flaviviruses.
- Authors: Balmaseda A, Stettler K, Medialdea-Carrera R, Collado D, Jin X, Zambrana JV, Jaconi S, Cameroni E, Saborio S, Rovida F, Percivalle E, Ijaz S, Dicks S, Ushiro-Lumb I, Barzon L, Siqueira P, Brown DWG, Baldanti F, Tedder R, Zambon M, de Filippis AMB, Harris E, Corti D
- Issue date: 2017 Aug 1
- Antibody Responses to Zika Virus Infections in Environments of Flavivirus Endemicity.
- Authors: Keasey SL, Pugh CL, Jensen SMR, Smith JL, Hontz RD, Durbin AP, Dudley DM, O'Connor DH, Ulrich RG
- Issue date: 2017 Apr
- Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus.
- Authors: Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S, Pattanapanyasat K, Chokephaibulkit K, Mulligan MJ, Wilson PC, Ahmed R, Suthar MS, Wrammert J
- Issue date: 2016 Jul 12